QNCX Quince Therapeutics: Rasio rega marang prakiraan pendapatan

Quince Therapeutics, Inc. - logo grafis emiten QNCX

Quince Therapeutics (QNCX) integrates ESG standards into the development of metabolic drugs while adhering to strict bioethics. The company is developing the AOC platform for erythrocyte-mediated drug delivery to reduce therapy toxicity. The estimated forward P/S reflects the business valuation relative to expected revenues, where the value serves as the current metric. The operating model relies on a virtual structure with full production outsourcing.

Quince Therapeutics Inc - Rasio kapitalisasi marang dodolan sing dikarepake QNCX (periode 04.07.2022 - 17.11.2026)

Ringkesan rincian data analitis Quince Therapeutics Inc (QNCX)

Analisis dhasar perusahaan:Quince Therapeutics (QNCX)
Produk asli Quince Therapeutics, Inc.

For Quince Therapeutics (QNCX), whose success depends on the clinical trial results of drug delivery systems, the forward price-to-sales ratio reflects market expectations for the future commercialization of molecules. This indicator is calculated as the ratio of current market capitalization to projected sales, allowing investors to assess the premium paid for future growth and determine whether the asset's current valuation is justified or speculative.

Pesaing Quince Therapeutics

Rasio rega marang prakiraan pendapatan ascendispharma.com ASND|Madrigal Corp (MDGL) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|CORT - Rasio rega marang prakiraan pendapatan|RYTM: Rasio rega marang prakiraan pendapatan|AKRO: Multiplikator Forward P/S|MTSR - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan MoonLake Corp|Crinetics Corp (CRNX) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan newamsterdampharma.com (NAMS)|Multiplikator forward rega marang pendapatan soleno.life SLNO|Multiplikator Forward P/S FOLD (amicusrx.com)|Rasio kapitalisasi marang dodolan sing dikarepake 89bio (ETNB)|Agios - Multiplikator Forward P/S|Structure Corp - Rasio rega marang pendapatan sing dikarepake|mimedx.com (MDXG) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan RZLT (rezolutebio.com)|LXRX (Lexicon Pharmaceuticals Inc) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan MBX|Rasio rega marang prakiraan pendapatan Altimmune Pharma (ALT)|Rasio rega marang prakiraan pendapatan AARD (Aardvark Therapeutics Corp)|Multiplikator Forward P/S SGMT (Sagimet Biosciences, Inc.)|BioAge (BIOA) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|BMEA: Multiplikator forward rega marang pendapatan|GUTS: Rasio rega marang prakiraan pendapatan|vTv Therapeutics Inc (VTVT) - Rasio rega marang prakiraan pendapatan|ATPC: Rasio rega marang pendapatan sing dikarepake|PLUR (pluri-biotech.com) - Multiplikator Forward P/S|SYBX: Rega forward marang dodolan|Multiplikator Forward P/S LPCN|Rasio kapitalisasi marang dodolan sing dikarepake Matinas BioPharma Holdings, Inc.|Rasio rega marang prakiraan pendapatan Spruce Biosciences Inc. SPRB|GLTO - Multiplikator forward rega marang pendapatan|CTCX - Rasio rega marang prakiraan pendapatan|LUMO - Multiplikator Forward P/S|ONVO: Multiplikator Forward P/S|RDUS (Radius Recycling) - Rasio rega marang prakiraan pendapatan